We further performed histochemical staining of clinical specimens derived from PDX models of breast and ovarian cancer and similarly verified that GCH1 expression was substantially higher in the niraparib-treated group compared with the control group (Figure 2(d)). The gene discussed is GCH1; the disease is ovarian cancer.